Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 301–400 of 1,001
New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome
Tiraboschi, E., Martina, S., van der Ent, W., Grzyb, K., Gaweł, K., Cordero-Maldonado, M. L., Poovathingal, S. K., Heintz, S., Satheesh, S. V., Brattespe, J., et al. (2020) · Epilepsia · doi:10.1111/epi.16456 · Cited by 82
Effective long-term treatment of obesity: a continuing care model
Latner, J. D., Stunkard, A. J., Wilson, G., Jackson, M., Zelitch, D., & Labouvie, E. W. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801249 · Cited by 80
Pharmacologic Therapies for Obesity
Kaplan, L. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.01.001 · Cited by 76
Cardiovascular outcome trials in obesity: A review
Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews · doi:10.1111/obr.13112 · Cited by 75
“A Mayo Clinic case series showed significant valvular heart disease in 24 women who had taken fen-phen for ≥6 months.(40) A subsequent report revealed that 113/132 (86%) peo-”
BackgroundSerotonin and Appetite Regulation: Implications for the Pharmacological Treatment of Obesity
Blundell, J. E., & Halford, J. C. G. (1998) · CNS Drugs · doi:10.2165/00023210-199809060-00005 · Cited by 75
Animal models of anorexia and cachexia
DeBoer, M. D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903300842 · Cited by 74
Cui, C., Li, Y., Gao, H., Zhang, H., Han, J., Zhang, D., Li, Y., Zhou, J., Lu, C., & Su, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186216 · Cited by 69
Sullivan, J., Scheffer, I. E., Lagae, L., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B., Lock, M., Agarwal, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16722 · Cited by 69
Cardiac, Vascular, and Skeletal Muscle Systems
Berridge, B. R., Vleet, J. F. V., & Herman, E. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415759-0.00046-7 · Cited by 73
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
Dahl, C. F., Allen, M. R., Urie, P. M., & Hopkins, P. N. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-34 · Cited by 73
Ryan, D. H., Bray, G. A., Helmcke, F., Sander, G., Volaufova, J., Greenway, F., Subramaniam, P., & Glancy, D. L. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00414.x · Cited by 74
Pharmacological treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200024 · Cited by 87
Zannad, F., Gille, B., Grentzinger, A., Bruntz, J.-F., Hammadi, M., Boivin, J.-M., Hanotin, C., Igau, B., & Drouin, P. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124403 · Cited by 71
Cardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 76
Munzar, P., Baumann, M. H., Shoaib, M. C., & Goldberg, S. R. (1999) · Psychopharmacology · doi:10.1007/s002130050836 · Cited by 72
Droogmans, S., Franken, P. R., Garbar, C., Weytjens, C., Cosyns, B., Lahoutte, T., Caveliers, V., Pipeleers‐Marichal, M., Bossuyt, A. M., Schoors, D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm263 · Cited by 73
Finer, N. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0231 · Cited by 80
Hotze, T. D., Shah, K. R., Anderson, E. E., & Wynia, M. K. (2011) · The American Journal of Bioethics · doi:10.1080/15265161.2011.534957 · Cited by 76
“Moreover, given the safety track record of some purported enhancement medicines, such as the weight-loss drug Fen-Phen, concern about the safety of enhancement medicines is not unwarranted (Connolly et al. 1997).”
BackgroundScience, medicine, and the future: Obesity treatment
Wilding, J. P. H. (1997) · BMJ · doi:10.1136/bmj.315.7114.997 · Cited by 89
Hughes, T. E., Kim, D. D., Marjason, J., Proietto, J., Whitehead, J. P., & Vath, J. E. (2013) · Obesity · doi:10.1002/oby.20356 · Cited by 66
Cosyns, J., Goebbels, R., Liberton, V., Schmeiser, H. H., Bieler, C. A., & Bernard, A. (1998) · Archives of Toxicology · doi:10.1007/s002040050568 · Cited by 69
“…was associated with pulmonary hypertension and valvular heart disease characterized by macroscopic thickening and microscopic ®brotic changes of the cardiac valve lea¯ets and chordae indistinguishable from the features of carcinoid and ergotamine-induced valve disease (Connolly et al. 1997).”
BackgroundInfluentialOyama, M. A., & Levy, R. J. (2009) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2009.0411.x · Cited by 82
Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014103 · Cited by 71
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Recent advances in carcinoid pathogenesis, diagnosis and management
Ganim, R. B., & Norton, J. A. (2000) · Surgical Oncology · doi:10.1016/s0960-7404(01)00007-x · Cited by 69
The challenge of defining normality for human mitral and aortic valves
McDonald, P. C., Wilson, J. E., McNeill, S., Gao, M., Spinelli, J. J., Rosenberg, F. M., Wiebe, H., & McManus, B. M. (2002) · Cardiovascular Pathology · doi:10.1016/s1054-8807(01)00102-8 · Cited by 69
“versy about the presence and basis of anorexigen-related valvular dysfunction [27–29].”
BackgroundThe Progression of Fenfluramine-Associated Valvular Heart Disease Assessed by Echocardiography
Mast, S. T., Jollis, J. G., Ryan, T., Anstrom, K. J., & Crary, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00008 · Cited by 69
Self-citationMedicinal chemistry strategies in follow-on drug discovery
Zhao, H., & Guo, Z. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.008 · Cited by 73
Gustafsson, B. I., Westbroek, I., Waarsing, J. H., Waldum, H., Solligård, E., Brunsvik, A., Dimmen, S., van Leeuwen, J. P. T. M., Weinans, H., & Syversen, U. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20733 · Cited by 67
Jensen, G. L., & Rogers, J. Z. (1998) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(98)00293-4 · Cited by 68
New Obesity Agents: Lorcaserin and Phentermine/Topiramate
Fleming, J. W., McClendon, K. S., & Riche, D. M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r779 · Cited by 73
Wold, E. A., Wild, C., Cunningham, K. A., & Zhou, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190709101449 · Cited by 69
Screening the receptorome: an efficient approach for drug discovery and target validation
Strachan, R. T., Ferrara, G., & Roth, B. L. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.012 · Cited by 75
Setola, V., Dukat, M., Glennon, R. A., & Roth, B. L. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009266 · Cited by 71
“Fenfluramine was also known to be associated with pulmonary hypertension (PH) (Brenot et al., 1993; Connolly et al., 1997; Pouwels et al., 1990; Simonneau et al., 1998).”
BackgroundInfluentialEffects of Neuropeptides and Leptin on Nutrient Partitioning: Dysregulations in Obesity
Jeanrenaud, B., & Rohner-Jeanrenaud, F. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.339 · Cited by 66
Drug-induced valvular heart disease: An update
Andréjak, M., & Tribouilloy, C. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.02.003 · Cited by 69
New therapeutic opportunities for 5-HT2 receptor ligands
Maroteaux, L., Ayme‐Dietrich, E., Aubertin-Kirch, G., Banas, S. M., Quentin, E., Lawson, R., & Monassier, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.008 · Cited by 66
Drug-Induced Pulmonary Disease
Dulohery, M. M., Maldonado, F., & Limper, A. H. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00071-3 · Cited by 66
Current Concepts in the Pharmacological Management of Obesity
Carek, P. J., & Dickerson, L. M. (1999) · Drugs · doi:10.2165/00003495-199957060-00005 · Cited by 76
Echocardiographic Improvement Over Time After Cessation of Use of Fenfluramine and Phentermine
Hensrud, D. D., Connolly, H. M., Grogan, M. A., Miller, F. A., Bailey, K. R., & Jensen, M. D. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.12.1191 · Cited by 66
Self-citationPalaniswamy, C., Frishman, W. H., & Aronow, W. S. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31824c866e · Cited by 65
Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Elangbam, C. S. (2009) · Veterinary Pathology · doi:10.1354/vp.46-1-10 · Cited by 66
Weissman, N. J., Sanchez, M., Koch, G. G., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2013) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.000128 · Cited by 70
Treatment Strategies for Dravet Syndrome
Knupp, K. G., & Wirrell, E. C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0511-y · Cited by 71
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Odi, R., Invernizzi, R. W., Gallily, T., Bialer, M., & Perucca, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107866 · Cited by 66
Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease
Żółkowska, D., Rothman, R. B., & Baumann, M. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101618 · Cited by 68
“Many investigators have theorized that fenfluramine increases the risk of PPH and VHD by elevating plasma 5-HT levels in blood, consistent with its known 5-HT-releasing properties in nervous tissue (Connolly et al., 1997; Fishman, 1999; MacLean et al., 2000).”
BackgroundTintner, R., Manian, P., Gauthier, P., & Jankovic, J. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1290 · Cited by 65
Baumann, M. H., Ayestas, M. A., Dersch, C. M., & Rothman, R. B. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00221-9 · Cited by 71
“dtd" [ ]> The amphetamine derivatives d,l- fenfluramine (FEN) and d -fenfluramine (dFEN) were widely prescribed appetite suppressants until their removal from the market due to serious side-effects (”
BackgroundKumar, V., Singh, D. D., Lakhawat, S. S., Yasmeen, N., Pandey, A., & Singla, R. K. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6852276 · Cited by 71
“In the 1990s, fenfluramine and dexfenfluramine were withdrawn from the market because of heart valve damage [70].”
Background2-Phenethylamines in Medicinal Chemistry: A Review
Nieto, C. T., Manchado, A., Belda, L., Diez, D., & Garrido, N. M. (2023) · Molecules · doi:10.3390/molecules28020855 · Cited by 67
Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy
Rothman, R. B., & Baumann, M. H. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fde95 · Cited by 64
Pharmaceutical Cost Savings of Treating Obesity with Weight Loss Medications
Greenway, F. L., Ryan, D. H., Bray, G. A., Rood, J. C., Tucker, E. W., & Smith, S. R. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00709.x · Cited by 66
Effects on serotonin in rat hypothalamus of d-fenfluramine, aminorex, phentermine and fluoxetine
Tao, R., Fray, A. E., Aspley, S., Brammer, R. J., Heal, D. J., & Auerbach, S. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01751-x · Cited by 64
Developing Drugs for Core Social and Communication Impairment in Autism
Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.010 · Cited by 62
Greenway, F. L., & Caruso, M. K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1083 · Cited by 61
Huang, L., Wu, X., & Chen, J. Y. (2012) · PROTEOMICS · doi:10.1002/pmic.201200337 · Cited by 71
Sippel, R. S., & Chen, H. (2006) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2006.05.002 · Cited by 63
Central Serotonergic Activity is Related to the Aggressive Behaviors of Alzheimer's Disease
Lanctôt, K. L., Herrmann, N., Eryavec, G. M., van Reekum, R., Reed, K. W., & Naranjo, C. A. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00339-1 · Cited by 68
“Fenfluramine has been associated with cardiac valvulopathy after prolonged therapy (Connolly et al. 1997), but not single dose use, and behavioral side-effects have not been reported in patients with dementia (Mintzer et al. 1998).”
BackgroundMDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation
Bishop, C., Taylor, J. L., Kuhn, D. M., Eskow, K. L., Park, J. Y., & Walker, P. D. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04790.x · Cited by 62
Use of Prescription Weight Loss Pills among U.S. Adults in 1996–1998
Khan, L. K., Serdula, M. K., Bowman, B. A., & Williamson, D. F. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00011 · Cited by 64
Burger, A. J., Sherman, H. B., Charlamb, M. J., Kim, J., Asinas, L. A., Flickner, S., & Blackburn, G. L. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00321-6 · Cited by 63
Therapeutic advances in Dravet syndrome: a targeted literature review
Strzelczyk, A., & Schubert‐Bast, S. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1801423 · Cited by 64
Use and Misuse of BMI Categories
Flegal, K. M. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.550 · Cited by 71
Doggrell, S. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.5.805 · Cited by 67
Metabolic Abnormalities and the Role of Leptin in Human Obesity
Pi‐Sunyer, F. X., & Laferrère, B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5392-1 · Cited by 69
Obesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
Characterization of phentermine and related compounds as monoamine oxidase (mao) inhibitors
Ulus, İ. H., Maher, T. J., & Wurtman, R. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00306-3 · Cited by 61
Thrombotic Thrombocytopenic Purpura and Clopidogrel — A Need for New Approaches to Drug Safety
Wood, A. J. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422410 · Cited by 61
Fat-On-A-Chip Models for Research and Discovery in Obesity and Its Metabolic Comorbidities
McCarthy, M. E., Brown, T., Alarcon, A., Williams, C., Wu, X., Abbott, R. D., Gimble, J. M., & Frazier, T. P. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2019.0261 · Cited by 62
5-HT recruits distinct neurocircuits to inhibit hunger-driven and non-hunger-driven feeding
He, Y., Cai, X., Liu, H., Conde, K., Xu, P., Li, Y., Wang, C., Yu, M., He, Y., Liu, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01220-z · Cited by 62
Doslikova, B., Garfield, A. S., Shaw, J., Evans, M. L., Burdakov, D., Billups, B., & Heisler, L. K. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4326-12.2013 · Cited by 57
“However, such compounds have been withdrawn from clinical use due to off-target effects (Connolly et al., 1997).”
BackgroundReview of Medicinal Plants for Anti-Obesity Activity
Patra, S., & Nithya, S. (2015) · Translational Biomedicine · doi:10.21767/2172-0479.100021 · Cited by 60
Xu, M. J., Yang, L., Zhu, Y., Liao, M., Chu, L., Li, X., Lin, L., & Zheng, G. (2019) · Food & Function · doi:10.1039/c9fo00502a · Cited by 66
Callahan, B. T., Cord, B. J., & Ricaurte, G. A. (2001) · Synapse · doi:10.1002/syn.1032 · Cited by 60
Valvular Heart Disease Associated with Dexfenfluramine
Cannistra, L. B., Davis, S. M., & Bauman, A. G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370912 · Cited by 60
The Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 54
“However, a high rate of cardiac valvular abnormalities was noted in patients taking this combination, which led to the withdrawal of fenfluramine from the market.(35) Phentermine monotherapy has not been linked to disproportionate incidence of cardiac valvular disease.”
BackgroundWeight Gain, Obesity, and Psychotropic Prescribing
Nihalani, N. D., Schwartz, T. L., Siddiqui, U. A., & Megna, J. L. (2011) · Journal of Obesity · doi:10.1155/2011/893629 · Cited by 71
Pharmaceutical approaches to the treatment of obesity
Jandacek, R. J., & Woods, S. C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03244-1 · Cited by 64
Weight Loss and Gender: An Examination of Physician Attitudes
Anderson, C., Peterson, C. B., Fletcher, L., Mitchell, J. E., Thuras, P., & Crow, S. J. (2001) · Obesity Research · doi:10.1038/oby.2001.30 · Cited by 59
“The second part of the questionnaire included a grid with 11 possible treatment options: 1) refer to another health care professional who specializes in weight loss; 2) refer to a dietitian or nutritionist; 3) refer to Weight Watchers or another commercial weight loss program; 4) suggest an increase in the frequency o…”
BackgroundThe new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
New pharmacological approaches for obesity management
Rueda‐Clausen, C. F., Padwal, R. S., & Sharma, A. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.113 · Cited by 61
The potential use of selective 5-HT2Cagonists in treating obesity
Smith, B. M., Thomsen, W. J., & Grottick, A. J. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.257 · Cited by 62
Lee, M. D., Somerville, E. M., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1864-0 · Cited by 58
Mcmillan, E., Martin, W. L., Waugh, J., Rushton, I., Lewis, M., Clutton-Brock, T. H., Townend, J., Kilby, M. D., & Gordon, C. (2002) · Lupus · doi:10.1191/0961203302lu216xx · Cited by 58
Wee, C. C., Phillips, R. S., Aurigemma, G., Erban, S., Kriegel, G., Riley, M., & Douglas, P. S. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-11_part_1-199812010-00005 · Cited by 58
Pharmacological treatment of obesity: present status
Scheen, A. J., & Lefèbvre, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800795 · Cited by 63
Psychedelics as Transformative Therapeutics
Roth, B. L., & Gumpper, R. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230172 · Cited by 58
Saunders, K. H., Shukla, A. P., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.005 · Cited by 60
Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves
Silva, R. A. P., Miller, J. D., Chu, Y., & Heistad, D. D. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00570.2009 · Cited by 58
Pediatric Obesity: Etiology and Treatment
Crocker, M. K., & Yanovski, J. A. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.004 · Cited by 71
Knupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2023) · Epilepsia · doi:10.1111/epi.17431 · Cited by 55
Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin
Connolly, J. M., Bakay, M. A., Fulmer, J. T., Gorman, R. C., Gorman, J. H., Oyama, M. A., & Levy, R. J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081101 · Cited by 58
Adams, T. D., Avelar, E., Cloward, T. V., Crosby, R. D., Farney, R. J., Gress, R. E., Halverson, R. L., Hopkins, P. N., Kolotkin, R. L., LaMonte, M. J., et al. (2005) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.05.003 · Cited by 55
Why are anti-obesity drugs stigmatized?
Halpern, B., & Halpern, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.995088 · Cited by 61
Sullivan, J. E., Lagae, L. G., Cross, J. H., Devinsky, O., Guerrini, R., Knupp, K. G., Laux, L., Nikanorova, M., Polster, T., Talwar, D., et al. (2023) · Epilepsia · doi:10.1111/epi.17737 · Cited by 55
Erritzøe, D., Ashok, A. H., Searle, G. E., Colasanti, A., Turton, S., Lewis, Y. L., Huiban, M., Moz, S., Passchier, J., Saleem, A., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0567-5 · Cited by 54
“In contrast to fenfluramine which was withdrawn from the market two decades ago [38], d-amphetamine is readily available for human research and is considered to be safe as an acute pharmacological challenge.”
BackgroundLavelle, A., Honner, V., & Docherty, J. R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702875 · Cited by 54
“Certainly, chronic use of methamphetamine may also result in serious cardiovascular changes including tachycardia and palpitations (Chan et al., 1994), and another amphetamine derivative, fen¯uramine has been linked to valvular heart disease (Connolly et al., 1997).”
BackgroundPsychological factors affecting a medical condition
Ketterer, M. W., Mahr, G., & Goldberg, A. D. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00099-4 · Cited by 59
Anorectic Drugs and Pulmonary Hypertension from the Bedside to the Bench
Michelakis, E. D., & Weir, Ε. K. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200104000-00009 · Cited by 54
Carcinoid heart disease: Diagnosis and management
Luis, S. A., & Pellikka, P. A. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.09.005 · Cited by 53
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.